Next Article in Journal
Health Literacy, Vaccine Confidence and Influenza Vaccination Uptake among Nursing Home Staff: A Cross-Sectional Study Conducted in Tuscany
Next Article in Special Issue
Identification of Toxoplasma Gondii Tyrosine Hydroxylase (TH) Activity and Molecular Immunoprotection against Toxoplasmosis
Previous Article in Journal
A Qualitative Study of Views and Experiences of Women and Health Care Professionals about Free Maternal Vaccinations Administered at Community Pharmacies
Previous Article in Special Issue
Recombinant Rabies Virus Overexpressing OX40-Ligand Enhances Humoral Immune Responses by Increasing T Follicular Helper Cells and Germinal Center B Cells

Progress and Prospects on Vaccine Development against SARS-CoV-2

National Engineering Research Center of Immunological Products, Department of Microbiology and Biochemical Pharmacy, College of Pharmacy and Laboratory Medicine, Third Military Medical University, Chongqing 400038, China
Laboratory of the Immune System Biology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
Authors to whom correspondence should be addressed.
Vaccines 2020, 8(2), 153;
Received: 11 March 2020 / Revised: 26 March 2020 / Accepted: 26 March 2020 / Published: 29 March 2020
In December 2019, the outbreak of pneumonia caused by a novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has led to a serious pandemic in China and other countries worldwide. So far, more than 460,000 confirmed cases were diagnosed in nearly 190 countries, causing globally over 20,000 deaths. Currently, the epidemic is still spreading and there is no effective means to prevent the infection. Vaccines are proved to be the most effective and economical means to prevent and control infectious diseases. Several countries, companies, and institutions announced their programs and progress on vaccine development against the virus. While most of the vaccines are under design and preparation, there are some that have entered efficacy evaluation in animals and initial clinical trials. This review mainly focused on the progress and our prospects on field of vaccine development against SARS-CoV-2. View Full-Text
Keywords: SARS-CoV-2; vaccine; adjuvant; animal model SARS-CoV-2; vaccine; adjuvant; animal model
Show Figures

Figure 1

MDPI and ACS Style

Zhang, J.; Zeng, H.; Gu, J.; Li, H.; Zheng, L.; Zou, Q. Progress and Prospects on Vaccine Development against SARS-CoV-2. Vaccines 2020, 8, 153.

AMA Style

Zhang J, Zeng H, Gu J, Li H, Zheng L, Zou Q. Progress and Prospects on Vaccine Development against SARS-CoV-2. Vaccines. 2020; 8(2):153.

Chicago/Turabian Style

Zhang, Jinyong, Hao Zeng, Jiang Gu, Haibo Li, Lixin Zheng, and Quanming Zou. 2020. "Progress and Prospects on Vaccine Development against SARS-CoV-2" Vaccines 8, no. 2: 153.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop